Sign In

Login

Password

Forgot Password ? Sign Up

レナリドミド (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "レナリドミド" in Japanese language version.

refsWebsite
Global rank Japanese rank
11nih.gov
4th place
24th place
5doi.org
2nd place
6th place
2pmda.go.jp
6,690th place
394th place
1mhlw.go.jp
1,656th place
110th place
1ncc.go.jp
low place
1,936th place
1interq.or.jp
low place
4,543rd place
1myeloma.gr.jp
low place
low place
1druglib.com
low place
low place
1drugbank.ca
4,294th place
low place

doi.org

  • Weber DM, Chen C, Niesvizky R, et al. (November 2007). “Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America”. The New England Journal of Medicine 357 (21): 2133–42. doi:10.1056/NEJMoa070596. PMID 18032763. 
  • Armoiry X, Aulagner G, Facon T (June 2008). “Lenalidomide in the treatment of multiple myeloma: a review”. Journal of Clinical Pharmacy and Therapeutics 33 (3): 219–26. doi:10.1111/j.1365-2710.2008.00920.x. PMID 18452408. 
  • Zhu, Y. X.; Braggio, E; Shi, C. X.; Bruins, L. A.; Schmidt, J. E.; Van Wier, S; Chang, X. B.; Bjorklund, C. C. et al. (2011). “Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide”. Blood 118 (18): 4771–9. doi:10.1182/blood-2011-05-356063. PMC 3208291. PMID 21860026. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208291/. 
  • Stewart, A. K. (2014). “Medicine. How thalidomide works against cancer”. Science 343 (6168): 256–7. doi:10.1126/science.1249543. PMC 4084783. PMID 24436409. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084783/. 
  • Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL (2015). “Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS”. Nature 523 (7559): 183-188. doi:10.1038/nature14610. PMC 4853910. PMID 26131937. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853910/. 

drugbank.ca

  • “Lenalidomide”. DrugBank (2010年12月23日). 2011年4月3日閲覧。

druglib.com

interq.or.jp

mhlw.go.jp

myeloma.gr.jp

ncc.go.jp

ganjoho.ncc.go.jp

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Weber DM, Chen C, Niesvizky R, et al. (November 2007). “Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America”. The New England Journal of Medicine 357 (21): 2133–42. doi:10.1056/NEJMoa070596. PMID 18032763. 
  • Armoiry X, Aulagner G, Facon T (June 2008). “Lenalidomide in the treatment of multiple myeloma: a review”. Journal of Clinical Pharmacy and Therapeutics 33 (3): 219–26. doi:10.1111/j.1365-2710.2008.00920.x. PMID 18452408. 
  • Zhu, Y. X.; Braggio, E; Shi, C. X.; Bruins, L. A.; Schmidt, J. E.; Van Wier, S; Chang, X. B.; Bjorklund, C. C. et al. (2011). “Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide”. Blood 118 (18): 4771–9. doi:10.1182/blood-2011-05-356063. PMC 3208291. PMID 21860026. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208291/. 
  • Stewart, A. K. (2014). “Medicine. How thalidomide works against cancer”. Science 343 (6168): 256–7. doi:10.1126/science.1249543. PMC 4084783. PMID 24436409. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084783/. 
  • Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL (2015). “Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS”. Nature 523 (7559): 183-188. doi:10.1038/nature14610. PMC 4853910. PMID 26131937. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853910/. 

ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

pmda.go.jp

info.pmda.go.jp